<DOC>
	<DOCNO>NCT01855841</DOCNO>
	<brief_summary>ERCP ( endoscopic retrograde cholangiopancreatography ) largely demonstrated effective multiple bilio-pancreatic indication . However , one fear complication technique acute pancreatitis , happen 5 25 % case . Some patient group demonstrate present high risk link individual factor procedure . Some intervention ( endoscopic pharmacologic ) evaluate reduce incidence complication inconvenient . Recently , activation heme oxygenase ( HO ) intraperitoneal administration hemin demonstrate effective prevention treatment acute pancreatitis mouse model . This protective effect associate intrapancreatic HO-1 positive macrophage recruitment activate hemin . The investigator thus propose conduct prospective randomize double blind control trial demonstrate protective effect hemin administration post-ERCP acute pancreatitis high risk patient .</brief_summary>
	<brief_title>Hemin Prevent Post-ERCP ( Endoscopic Retrograde Cholangiopancreatography ) Acute Pancreatitis</brief_title>
	<detailed_description>Patients pancreatic stent placement indicate exclude study . The aim study : 1 ) study pathophysiologic point view activation HO-1 hemin human protective effect post-ERCP acute pancreatitis incidence . 2 ) use human situation post-ERCP acute pancreatitis early pancreatitis model study administration hemin treatment acute pancreatitis general .</detailed_description>
	<mesh_term>Pancreatitis</mesh_term>
	<criteria>one factor &gt; 10 % postERCP acute pancreatitis risk : former episode acute pancreatitis former episode postERCP acute pancreatitis normal bilirubin level main pancreatic duct injection endoscopic biliary sphincteroplasty ( balloon dilation biliary sphincter ) precut papillotomy pancreatic sphincterotomy patient pancreatic stent insert ( Sphincter Oddi dysfunction , ampullectomy ) ongoing acute pancreatitis chronic pancreatitis ( Cremer classification &gt; =2 ) age &lt; 18 y/o pregnancy hemin allergy severe renal failure ( MDRD &lt; 30ml/min/1.73m2 )</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>March 2017</verification_date>
	<keyword>ERCP</keyword>
	<keyword>virgin papilla</keyword>
	<keyword>risk post-ERCP acute pancreatitis</keyword>
</DOC>